Omega Fund Management LLC Lowers Stake in Replimune Group, Inc. (NASDAQ:REPL)

Omega Fund Management LLC trimmed its holdings in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 19.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,975,203 shares of the company's stock after selling 486,116 shares during the period. Replimune Group comprises approximately 19.9% of Omega Fund Management LLC's portfolio, making the stock its 3rd largest position. Omega Fund Management LLC owned about 2.89% of Replimune Group worth $23,920,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD grew its stake in shares of Replimune Group by 11.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 10,962,883 shares of the company's stock worth $132,761,000 after purchasing an additional 1,083,633 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Replimune Group by 3.7% during the 4th quarter. Vanguard Group Inc. now owns 3,595,848 shares of the company's stock worth $43,546,000 after acquiring an additional 129,601 shares during the period. Boxer Capital Management LLC purchased a new position in shares of Replimune Group during the 4th quarter worth approximately $21,754,000. Millennium Management LLC grew its holdings in shares of Replimune Group by 3.0% during the 4th quarter. Millennium Management LLC now owns 1,189,662 shares of the company's stock worth $14,407,000 after acquiring an additional 34,841 shares during the period. Finally, Wellington Management Group LLP grew its holdings in shares of Replimune Group by 352.5% during the 4th quarter. Wellington Management Group LLP now owns 1,096,744 shares of the company's stock worth $13,282,000 after acquiring an additional 854,346 shares during the period. 92.53% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the company. HC Wainwright upped their target price on Replimune Group from $21.00 to $22.00 and gave the stock a "buy" rating in a report on Thursday, February 13th. JPMorgan Chase & Co. upped their target price on Replimune Group from $16.00 to $18.00 and gave the stock an "overweight" rating in a report on Wednesday, February 26th. Finally, BMO Capital Markets boosted their price target on Replimune Group from $18.00 to $27.00 and gave the stock an "outperform" rating in a research report on Wednesday, January 22nd. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Replimune Group presently has an average rating of "Buy" and a consensus price target of $19.43.

Replimune Group Stock Up 8.6%

Shares of REPL traded up $0.62 during mid-day trading on Friday, reaching $7.85. The company had a trading volume of 1,666,221 shares, compared to its average volume of 904,125. The company has a debt-to-equity ratio of 0.14, a quick ratio of 11.43 and a current ratio of 11.43. The firm has a 50-day moving average price of $8.95 and a 200 day moving average price of $11.32. Replimune Group, Inc. has a 52 week low of $4.92 and a 52 week high of $17.00. The company has a market capitalization of $604.57 million, a price-to-earnings ratio of -2.56 and a beta of 0.68.

Replimune Group (NASDAQ:REPL - Get Free Report) last released its quarterly earnings data on Wednesday, February 12th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by ($0.09). On average, sell-side analysts forecast that Replimune Group, Inc. will post -2.97 EPS for the current year.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.